New Technology / Ai Development
AI Innovations in Reproductive Health
Biotics AI, co-founded by Robbie Bustami, is developing an AI co-pilot for ultrasound aimed at improving the detection of fetal abnormalities. The company addresses significant misdiagnosis issues that impact many pregnant patients, with a focus on enhancing diagnostic accuracy through innovative technology.
Source material: Keeping Your Team Motivated When FDA Approval Isn’t Guaranteed l Build Mode
Summary
Biotics AI, co-founded by Robbie Bustami, is developing an AI co-pilot for ultrasound aimed at improving the detection of fetal abnormalities. The company addresses significant misdiagnosis issues that impact many pregnant patients, with a focus on enhancing diagnostic accuracy through innovative technology.
The company successfully developed a working prototype for under $100,000, a notable achievement in the medical device sector. Winning the Startup Battlefield in 2023 significantly boosted Biotics AI's visibility and facilitated clinical partnerships, which are crucial for advancing their FDA clinical studies.
Biotics AI's AI software enhances ultrasound machines by providing real-time feedback, ensuring comprehensive capture of fetal anatomy during screenings. This technology aims to minimize misdiagnosis risks, which currently affect half of pregnant patients with fetal malformations.
Achieving FDA clearance marked a pivotal moment for Biotics AI, allowing the company to launch its product in hospitals across the United States. The journey to this point involved meticulous planning and alignment of product development with regulatory requirements.
Perspectives
Biotics AI's Approach
- Develops an AI co-pilot for ultrasound to improve fetal abnormality detection
- Achieved FDA clearance, allowing for product launch in hospitals
Challenges in MedTech
- Navigating the FDA approval process is lengthy and complex
Neutral / Shared
- AI technology aims to reduce misdiagnosis rates in fetal abnormalities
- Building a diverse team is crucial for addressing the challenges in product development
Metrics
less than $100,000 USD
cost of the prototype
This cost is significant in the medical device sector, indicating efficient resource use
we had built up a functioning product for less than $100,000
2023
year of winning Startup Battlefield
Winning this competition can accelerate growth and funding opportunities
Biotics AI won the start of battlefield in 2023
15 units
of maternal field medicine specialists
A dedicated team size indicates a strong commitment to clinical validation
we built out a team of roughly 15 maternal field medicine specialists
over 3,000 startups units
of applicants for Startup Battlefield
This highlights the competitive landscape Biotics AI navigated to achieve recognition
over 3,000 startups that had applied
less than $100,000 USD
cost of developing a functioning product
This cost is notably low for the medical device space, indicating efficient resource management
we had built out a functioning product for less than $100,000
about 30 individuals units
total team members involved in the startup
A diverse team is crucial for managing various aspects of a medtech startup
it's about 30 individuals
Key entities
Key developments
Phase 1
Biotics AI is developing an AI co-pilot for ultrasound to improve the detection of fetal abnormalities, addressing significant misdiagnosis issues. The company successfully created a prototype for under $100,000 and won the Startup Battlefield in 2023, enhancing its visibility and partnerships.
- Biotics AI, co-founded by Robbie Bustami, is creating an AI co-pilot for ultrasound aimed at improving the detection of fetal abnormalities, addressing misdiagnosis issues that impact many pregnant patients
- The company successfully developed a working prototype for under $100,000, a significant achievement in the medical device sector, and gained visibility by presenting their solution during a live-streamed event
- Their AI software enhances ultrasound machines by providing real-time feedback, ensuring comprehensive capture of fetal anatomy during screenings to minimize misdiagnosis risks
- Winning the Startup Battlefield in 2023 was pivotal for Biotics AI, facilitating clinical partnerships and advancing their FDA clinical studies
- The necessity of building a diverse team of engineers, clinicians, and advisors to effectively navigate the challenges of product development in the highly regulated medtech field
Phase 2
Biotics AI has developed an AI co-pilot for ultrasound to improve the detection of fetal abnormalities, addressing significant misdiagnosis issues. The company achieved FDA clearance for its product, allowing it to launch in hospitals across the United States.
- Robbie Bustamis background in maternal care and technology, influenced by his familys medical profession and early coding interests, inspired him to create an AI solution for fetal diagnostics
- The AI co-pilot for ultrasound aims to significantly reduce misdiagnosis rates in fetal abnormalities, addressing the issue where half of pregnant patients with malformations are misdiagnosed due to operator errors
- The journey to FDA clearance began early in product development, focusing on safety, efficacy, and regulatory compliance, culminating in a successful submission last year
- Engaging with the FDA through pre-submission meetings helped align clinical studies with regulatory expectations, ensuring a robust validation process
- With FDA clearance achieved, BioticsAI is set to launch its product in hospitals across the United States, marking a significant milestone in bringing their technology to market
Phase 3
Biotics AI is focused on enhancing ultrasound technology to better detect fetal abnormalities, aiming to improve maternal health outcomes. The company has achieved FDA clearance for its product, allowing it to launch in hospitals across the United States.
- BioticsAI is enhancing its ultrasound technology to identify specific fetal abnormalities and improve maternal health outcomes
- The company integrates clinical testing with its market strategy, utilizing partnerships with hospitals involved in their research to support product adoption
- Robbie Bustami highlights the necessity of team alignment across regulatory, product, and clinical domains to sustain motivation during the protracted FDA approval journey
- Proactive preparation and early incorporation of regulatory factors into product development can help reduce the risk of FDA rejection
- Staying updated on evolving FDA regulations is crucial for startups to effectively adjust their strategies
Phase 4
Biotics AI has developed an AI co-pilot for ultrasound, achieving FDA clearance to improve fetal abnormality detection. The company won the Startup Battlefield in 2023, enhancing its visibility and partnerships.
- BioticsAIs victory at the Startup Battlefield, where they ranked among the top 20 out of over 3,000 applicants, fostered a strong sense of community among innovative peers
- The TechCrunch team significantly aided BioticsAI in refining their narrative and effectively communicating their solution, which enhanced their outreach efforts
- A live demo featuring a pregnant woman resonated with the audience, leading to increased interest as physicians began sharing the demo video among themselves
- Early-stage MedTech founders encounter unique challenges, including extended product development timelines, rigorous clinical testing, and the need to validate safety and efficacy prior to market entry
- Fundraising in the MedTech sector is particularly difficult due to the high risks associated with regulated medical devices, resulting in a limited pool of specialized investors who comprehend the industrys complexities
Phase 5
Biotics AI has developed an AI co-pilot for ultrasound, achieving FDA clearance to improve fetal abnormality detection. The company emphasizes the importance of maintaining team motivation and strategic planning during the lengthy FDA approval process.
- Navigating the FDA approval process necessitates careful selection of consultants and advisors experienced with AI products, given the complexity and evolving nature of regulations
- Founders must prioritize efficiency and cost-effectiveness in product development, as expenses can rise rapidly; BioticsAI notably developed a functioning product for under $100,000
- Being mission-driven is crucial for health tech founders, who often face extended timelines and must stay focused on their ultimate goal of enhancing patient outcomes
- Its important to balance the roles of advisors and full-time team members; some physicians act as advisors while maintaining their practice, providing valuable insights and feedback
Phase 6
Biotics AI is developing an AI co-pilot for ultrasound technology to enhance fetal abnormality detection. The company has achieved FDA clearance and aims to expand its applications in reproductive health over the next five years.
- BioticsAI has a diverse team of around 30, including part-time researchers and medical professionals, to handle various aspects of their medtech startup
- The company compensates team members through hourly pay or equity, providing education on the associated risks and benefits of equity in a startup
- Founders should ensure that both advisors and team members are involved in revenue generation to align their interests with the companys success
- BioticsAI aims to lead in AI diagnostics for reproductive health, beginning with obstetrics and planning to expand into gynecology, urology, and neonatal care within five years
- The versatility of ultrasound as a diagnostic tool enables BioticsAI to tackle a broad spectrum of conditions, highlighting the significance of quality control and accurate diagnostics in their growth strategy